Scribe Therapeutics, Inc.
SCTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001853921
No open-market purchases or sales by Scribe Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q3 2026, worth $297.1M in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Scribe Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Scribe Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Andreessen Marc L | 10% Owner | 2,385,075Indirect | Jul 29, 2026 | 1 |
| Horowitz Benjamin A | 10% Owner | 2,385,075Indirect | Jul 29, 2026 | 1 |
| AH Bio Fund II, L.P. | 10% Owner | 2,385,075Indirect | Jul 29, 2026 | 1 |
| AH Equity Partners Bio II, L.L.C. | 10% Owner | 2,385,075Indirect | Jul 29, 2026 | 1 |
| AH Bio Fund III, L.P. | 10% Owner | 2,385,075Indirect | Jul 29, 2026 | 1 |
| AH Equity Partners Bio III, L.L.C. | 10% Owner | 2,385,075Indirect | Jul 29, 2026 | 1 |
| Gordon Carl L | Director | 1,348,825Indirect | Jul 29, 2026 | 2 |
| OrbiMed Advisors LLC | Director | 1,348,825Indirect | Jul 29, 2026 | 1 |
| OrbiMed Capital GP VIII LLC | Director | 1,348,825Indirect | Jul 29, 2026 | 1 |
| Doudna Jennifer A | 10% Owner | 603,547 | Jul 29, 2026 | 1 |
| Avoro Capital Advisors LLC | Director, 10% Owner, Other: See Remarks | 3,088,888Indirect | Jul 28, 2026 | 2 |
| Aghazadeh Behzad | Director, 10% Owner, Other: See Remarks | 3,088,888Indirect | Jul 28, 2026 | 2 |
| Avoro Ventures LLC | Director, Other: See Remarks | 3,088,888Indirect | Jul 28, 2026 | 2 |
| Staahl Brett | 10% Owner | – | Jul 28, 2026 | 1 |
| Lucas Svetlana | Chief Business Officer | 3,000Indirect | Jul 27, 2026 | 1 |
| Oakes Benjamin L. | President, CEO | – | Jul 27, 2026 | 1 |
| Watson James Dean | Director | – | Jul 27, 2026 | 1 |
| Bleharski Joshua | Director | – | Jul 27, 2026 | 1 |
| Parrot David | Chief Financial Officer | 1,333Indirect | Jul 27, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2026 (view filing)7:09 PM ET | Jul 27 | 2 days | Andreessen Marc L and 5 others10% Owner | PPurchase | +333.3K | $15.00 | +$5.00M | +16.2%2.39M after | |
| Jul 29, 2026 (view filing)6:50 PM ET | Jul 27 | 2 days | Gordon Carl LDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +286.7%1.35M after | Duplicate filing |
| Jul 29, 2026 (view filing)6:47 PM ET | Jul 27 | 2 days | OrbiMed Advisors LLC and 1 otherDirector | PPurchase | +1.00M | $15.00 | +$15.0M | +286.7%1.35M after | |
| Jul 28, 2026 (view filing)9:30 PM ET | Jul 24-28 | 4 days | Avoro Capital Advisors LLC and 2 othersDirector, 10% Owner, Other: See Remarks | PPurchaseCommon Stock, par value $0.0001 per share | +2.39M | $15.16 | +$36.3M | +342.8%3.09M after | 3 lots |
| Jul 27, 2026 (view filing)9:42 PM ET | Jul 23 | 4 days | Lucas SvetlanaChief Business Officer | PPurchase | +3.00K | $15.00 | +$45.0K | New position3.00K after | |
| Jul 27, 2026 (view filing)9:20 PM ET | Jul 23 | 4 days | Parrot DavidChief Financial Officer | PPurchase | +2.67K | $15.00 | +$40.0K | New position1.33K after | 2 lots |